CTOs on the Move

Geneos Therapeutics

www.geneostx.com

 
Geneos is developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.geneostx.com
  • 660 West Germantown Pike LL 100
    Plymouth Meeting, PA USA 19462
  • Phone: 358.9436.6250

Executives

Name Title Contact Details

Funding

Geneos Therapeutics raised $10.5M on 02/21/2019
Geneos Therapeutics raised $12M on 03/03/2021

Similar Companies

Isis Pharmaceuticals Inc

Isis Pharmaceuticals Inc is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medicure

Medicure is a specialty pharmaceutical company focused on the development and commercialization of therapeutics for the U.S. hospital market.

Abivax

Abivax is developing therapies that modulate the body`s natural immune system machinery. A clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to develop drug candidates to treat inflammatory diseases, viral diseases and liver cancer. Abivax is based on innovative research driven by the idea of modulating the body`s natural immune system mechanisms to treat diseases.

Semler Research Center Pvt.

Semler Research Center Pvt. Ltd. is a North Hollywood, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tyra Biosciences

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. TYRA is using its proprietary SNÅP platform, which is optimized to enable rapid and precise refinement of structural design through iterative molecular SNÅPshots, in order to generate next-generation product candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options. TYRA is initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. TYRA is advancing multiple product candidates toward the clinic including its lead product candidate TYRA-300, an FGFR3 inhibitor with an initial focus on patients with bladder cancer, and TYRA-200, an FGFR2 inhibitor with an initial focus on patients with intrahepatic cholangiocarcinoma who have developed drug resistance mutations from existing FGFR inhibitors.